Tirzepatide

Tirzepatide is a dual agonist — it activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. While semaglutide targets one receptor pathway, tirzepatide engages two, creating a compounded effect on appetite suppression, satiety signaling, and metabolic function. It's administered by subcutaneous injection, typically once weekly, with dosing titrated gradually under physician supervision. As with all prescriptions through OLIV Well, your specific protocol — including dose and administration schedule — is determined by your licensed telehealth provider based on your individual intake.

Tirzepatide was developed as a novel dual incretin receptor agonist and received FDA approval for type 2 diabetes management under the brand name Mounjaro in 2022. Clinical trials investigating its use for weight management — notably the SURMOUNT program — followed shortly after, enrolling tens of thousands of participants. Results from those trials showed body weight reductions that were among the largest reported in pharmacological weight management research. Tirzepatide subsequently received FDA approval for chronic weight management. Compounded tirzepatide prescribed through OLIV Well is produced at FDA-registered, 503A-compliant compounding pharmacies to pharmaceutical-grade standards and is not interchangeable with FDA-approved branded formulations.

Tirzepatide may cause side effects. The most commonly reported include nausea (most common, typically reduced with gradual dose titration), diarrhea, decreased appetite, vomiting, constipation, and abdominal pain. Less common but serious potential effects include pancreatitis and gallbladder disease. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use tirzepatide. This is not a complete list. Your OLIV Well provider will review your health history before prescribing and will discuss contraindications specific to your situation.

Function: Tirzepatide activates both GLP-1 and GIP receptors, creating a dual hormonal signal that reduces appetite, slows gastric emptying, and supports insulin sensitivity. The dual-receptor mechanism distinguishes it from single-agonist compounds and contributes to the magnitude of its metabolic effect. Benefit: For patients seeking a clinically supported weight management option, tirzepatide offers dual-pathway engagement that single-receptor agonists don't replicate. It addresses multiple metabolic levers simultaneously — making it a meaningful option for patients who haven't responded adequately to other approaches, or who are starting and want a well-studied compound with a strong clinical data set.